Yes, there is a significant drug interaction between apixaban and phenytoin that requires avoiding their concomitant use.
Phenytoin is a strong CYP3A4 and P-gp inducer that substantially decreases apixaban exposure, increasing the risk of stroke and thromboembolic events—therefore, avoid using apixaban with phenytoin. 1
Mechanism of Interaction
Apixaban is metabolized via CYP3A4 and is a substrate of P-glycoprotein (P-gp). Phenytoin acts as a combined strong inducer of both pathways, which accelerates apixaban metabolism and reduces its plasma concentrations 2. This pharmacokinetic interaction mirrors what has been documented with rifampin, another strong dual inducer, which significantly decreased apixaban area under the curve (AUC∞), leading to reduced anticoagulant efficacy and heightened thrombotic risk 2.
Clinical Evidence
The FDA label explicitly lists phenytoin among drugs to avoid with apixaban 1. Recent real-world data support this concern:
- A 2022 retrospective cohort study found high incidence rates of thromboembolism (4.4 per 100 person-years) in patients receiving DOACs with phenytoin, with DOAC levels measuring lower than expected in 47% of tested cases 3
- A 2025 cohort study of 1,843 patients on DOACs with CYP3A4/P-gp inducers (including phenytoin) showed no excess thrombotic risk compared to gabapentin, though this may reflect survivor bias and careful patient selection 4
- Multiple case reports document thromboembolic events when apixaban is combined with phenytoin 5, 6
- A 2025 systematic review confirmed that phenytoin co-administration with DOACs increases thromboembolic event risk 7
Management Algorithm
Step 1: Avoid the combination entirely 2, 1
- This is the primary recommendation from both FDA labeling and expert guidelines
- No dose adjustment of apixaban can reliably compensate for the degree of enzyme induction
Step 2: If anticoagulation is required in a patient on phenytoin:
Switch to warfarin as the preferred alternative 3, 7
- Warfarin allows INR monitoring to ensure therapeutic anticoagulation despite the interaction
- Phenytoin will still induce warfarin metabolism, but this can be managed with dose titration and frequent INR checks
- Expect higher warfarin doses will be needed
Consider edoxaban as a potential DOAC alternative 7
- Edoxaban has minimal CYP3A4 metabolism (primarily P-gp dependent)
- Limited evidence suggests it may be more acceptable than other DOACs with inducers
- However, robust clinical safety data are lacking—use with caution and consider drug level monitoring if available
Step 3: If phenytoin can be changed:
Switch to levetiracetam or gabapentin (non-enzyme-inducing antiepileptics) 4, 8
- Levetiracetam has no documented interaction with apixaban 8
- This allows safe continuation of apixaban therapy
Avoid other enzyme-inducing antiepileptics (carbamazepine, phenobarbital, primidone) as they pose similar risks 1, 4, 3
Critical Pitfalls to Avoid
Do not attempt dose escalation of apixaban without therapeutic drug monitoring—there is no established safe dosing regimen for this combination, and empiric dose increases risk both treatment failure and bleeding 2.
Do not assume the interaction resolves immediately after stopping phenytoin—enzyme induction effects may persist for 1-2 weeks after discontinuation due to phenytoin's long half-life and the time required for enzyme synthesis to normalize 9.
Be aware that 67% of apixaban drug interactions reported to VigiBase were not well-described or understood 5, highlighting that real-world interactions may be more complex than predicted from pharmacokinetic studies alone.
If the combination is unavoidable in rare circumstances (e.g., patient refuses warfarin, cannot switch antiepileptic), consider concentration-guided dosing with anti-Xa assays specific for apixaban, though this approach has limited validation 6, 10.